Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs

Shannon Gunawardana; William Tillett; Laura C. Coates

doi:10.1016/j.rdc.2025.05.007

Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs

Shannon Gunawardana, William Tillett, Laura C. Coates

Research output: Contribution to journal › Review article › peer-review

1 Citation (SciVal)

13 Downloads (Pure)

Abstract

Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthropathy with phenotypic, pathogenetic and radiological heterogeneity. Over the last 20 years, a wide range of biologic disease modifying anti-rheumatic drugs (bDMARDs) have been licensed for the treatment of PsA. Precision medicine aims to choose the right treatment for the right patient at the right time. Current clinical trials are using biomarker-targeted treatment approaches to guide bDMARD selection. There is ongoing debate as to whether a blood or tissue biomarker is the superior approach. Master protocol trials, including basket and umbrella trials, could revolutionise testing novel therapeutic strategies in PsA and seronegative spondyloarthropathies.

Original language	English
Pages (from-to)	495-509
Number of pages	15
Journal	Rheumatic Disease Clinics of North America
Volume	51
Issue number	3
Early online date	7 Jun 2025
DOIs	https://doi.org/10.1016/j.rdc.2025.05.007
Publication status	Published - 31 Aug 2025

Keywords

Basket trial
Difficult-to-treat
Precision medicine
Psoriatic arthritis
Umbrella trial

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/j.rdc.2025.05.007

Achieving_precision_medicine_in_PsAAccepted author manuscript, 364 KBLicence: CC BY

Cite this

@article{d4740395dc7a4a42bed5ecfc69069b1f,

title = "Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs",

abstract = "Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthropathy with phenotypic, pathogenetic and radiological heterogeneity. Over the last 20 years, a wide range of biologic disease modifying anti-rheumatic drugs (bDMARDs) have been licensed for the treatment of PsA. Precision medicine aims to choose the right treatment for the right patient at the right time. Current clinical trials are using biomarker-targeted treatment approaches to guide bDMARD selection. There is ongoing debate as to whether a blood or tissue biomarker is the superior approach. Master protocol trials, including basket and umbrella trials, could revolutionise testing novel therapeutic strategies in PsA and seronegative spondyloarthropathies. ",

keywords = "Basket trial, Difficult-to-treat, Precision medicine, Psoriatic arthritis, Umbrella trial",

author = "Shannon Gunawardana and William Tillett and Coates, \{Laura C.\}",

year = "2025",

month = aug,

day = "31",

doi = "10.1016/j.rdc.2025.05.007",

language = "English",

volume = "51",

pages = "495--509",

journal = "Rheumatic Disease Clinics of North America",

issn = "0889-857X",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Achieving Precision Medicine in Psoriatic Arthritis

T2 - Novel Treatment Strategies and Trial Designs

AU - Gunawardana, Shannon

AU - Tillett, William

AU - Coates, Laura C.

PY - 2025/8/31

Y1 - 2025/8/31

N2 - Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthropathy with phenotypic, pathogenetic and radiological heterogeneity. Over the last 20 years, a wide range of biologic disease modifying anti-rheumatic drugs (bDMARDs) have been licensed for the treatment of PsA. Precision medicine aims to choose the right treatment for the right patient at the right time. Current clinical trials are using biomarker-targeted treatment approaches to guide bDMARD selection. There is ongoing debate as to whether a blood or tissue biomarker is the superior approach. Master protocol trials, including basket and umbrella trials, could revolutionise testing novel therapeutic strategies in PsA and seronegative spondyloarthropathies.

AB - Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthropathy with phenotypic, pathogenetic and radiological heterogeneity. Over the last 20 years, a wide range of biologic disease modifying anti-rheumatic drugs (bDMARDs) have been licensed for the treatment of PsA. Precision medicine aims to choose the right treatment for the right patient at the right time. Current clinical trials are using biomarker-targeted treatment approaches to guide bDMARD selection. There is ongoing debate as to whether a blood or tissue biomarker is the superior approach. Master protocol trials, including basket and umbrella trials, could revolutionise testing novel therapeutic strategies in PsA and seronegative spondyloarthropathies.

KW - Basket trial

KW - Difficult-to-treat

KW - Precision medicine

KW - Psoriatic arthritis

KW - Umbrella trial

UR - https://www.scopus.com/pages/publications/105007434467

U2 - 10.1016/j.rdc.2025.05.007

DO - 10.1016/j.rdc.2025.05.007

M3 - Review article

AN - SCOPUS:105007434467

SN - 0889-857X

VL - 51

SP - 495

EP - 509

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

IS - 3

ER -

Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this